Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Dec 19, 2023
Eisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...
Read More...
Aug 07, 2023
Molluscum contagiosum, which affects around 6 million individuals in the United States, predominantly children, is a highly contagious viral skin disease characterized by unique, raised pinkish lesions that are irritating and often painful. These lumps can also cause inflammation and raise the risk of infection in ...
Read More...
Aug 12, 2022
Molluscum contagiosum, often known as water warts, is a common superficial skin disease caused by the poxvirus. The molluscum contagiosum virus (MCV) is one of the world's 50 most common diseases. It mostly affects school-aged children, sexually active young adults, and immunocompromised people. As per our...
Read More...
Jun 01, 2021
FDA Validates Use of Amgen’s KRAS Inhibitor in Lung Cancer In a pathbreaking move, Amgen has gone ahead to emerge as a trailblazer in the undruggable lung cancer space with the approval of its KRAS inhibitor, Lumakras. For eons, the researchers grappled to come up with an effective and potential drug to ta...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper